Roche's Troponin T Nominated for International Inventor Award
News Jun 11, 2012
The jury of the European Inventor Award has nominated the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg, for their invention concerning the "specific antibodies to troponin T, their production and their use in a reagent for the determination of heart muscle necrosis".
The Troponin T cardiac biomarker supports health professional decision making when faced with an emergency situation of a heart attack.
An early indication of myocardial injury can be detected by small elevations in cardiac troponin in the blood.
To enhance disease risk stratification, the Troponin T test supports a physician to early induce the right lifesaving actions during bedside symptom clarification.
Cardiac Troponins (cTn T or cTn I) are the preferred markers of myocardial injury but, until recently, cTn assays lacked sensitivity at the time of presentation and did not have the required level of precision at lower concentrations above the 99th percentile.
The Roche Elecsys® TnT hs assay is a highly sensitive cTn T assay that demonstrates excellent precision in the range of 0.003-10 ng/ml cTn T in serum or plasma and meets the required precision level of < 10% CV at the 99th percentile URL1.
Such sensitivity and precision is of enormous value in the assessment of patients presenting with cardiac symptoms - both in the early detection and in the early exclusion of AMI.
The performance of the Elecsys TnT hs assay is enhanced by its robustness against interfering factors, ensuring highly accurate results and consistency in patient follow up.
Furthermore, with results in as little as 9 minutes, it also delivers unprecedented speed and turnaround of results, which are essential for emergency samples.
In a recent study, the Elecsys hs TnT assay identified nearly 20% more patients with a final diagnosis of non-STEMI compared to a conventional cTn T assay and enabled an earlier diagnosis of non-STEMI.
The winners of the International Inventor Award will be announced and honored at a ceremony on June 14 at the Royal Danish Playhouse in Copenhagen. This year 15 inventions have been nominated in the category “industry”.
The European Inventor Award was launched by the European Patent Office in 2006 as the first European prize to honor outstanding inventions which contribute to innovation, economy and society.
The international jury is composed of members from politics, business and academia.
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE